On July 20, 2018, Kush M. Parmar, M.D., Ph.D., informed the Board of Directors of scPharmaceuticals Inc. of his resignation as a director and as a member of the Audit Committee and the Compensation Committee of the Board. Dr. Parmar's resignation was not related to any disagreement with the Company on any matter relating to its operations, policies, practices or any issues regarding financial disclosures, accounting or legal matters. On July 20, 2018, based on the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board increased the number of directors constituting the Board to nine and elected Minnie Baylor-Henry and Mason Freeman, M.D. to the Board. Concurrent with her election to the Board, Ms. Baylor-Henry was also elected as a member of the Nominating and Corporate Governance Committee. Dr. Freeman has not been elected to any committees of the Board at this time.